Challenges of BCLC stage C hepatocellular carcinoma Results of a single-institutional experience on stereotactic body radiation therapy

doi:10.1097/MD.0000000000021561

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/34098

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34098

Title:	Challenges of BCLC stage C hepatocellular carcinoma Results of a single-institutional experience on stereotactic body radiation therapy
Authors:	Que, Jenny Lin, Chia-Hui Lin, Li-Ching Ho, Chung-Han
Contributors:	Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Med Res
Keywords:	Barcelona clinic liver cancer stage C hepatocellular carcinoma stereotactic body radiation therapy
Date:	2020
Issue Date:	2022-11-18 11:23:50 (UTC+8)
Publisher:	Lippincott Williams & Wilkins
Abstract:	In this study, we evaluated the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). This retrospective study evaluated 139 patients with BCLC stage C HCC who underwent CyberKnife SBRT between January 2009 and September 2017. All patients had BCLC-C, Child-Turcotte-Pugh score A-B. In-field control, overall survival (OS), progression free survival (PFS), and prognostic factors were evaluated. An objective response rate was achieved in 81.5% patients (complete response, 36.2%, partial response, 45.3%). The median survival was 15.44 months, and the 1-, 3-, 5-year OS rates were 56%, 28%, and 20%, respectively. The median PFS was 6 months, the PFS rate at 1-, 3-, and 5-year were 35%, 14%, and 10%, respectively. In-field control of 1 to 2 years was achieved in 85.1% of patients. The major pattern of failure was out-field intrahepatic failure which comprised 42.9% of patients. Multivariate analysis revealed that the Child-Turcotte-Pugh score, macrovascular invasion, advance stage (III-IV), and tumor response rate were independent predictors of OS. The result of our study shows that SBRT is a safe and effective therapeutic option for BCLC stage C HCC lesions that are unsuitable for standard loco-regional therapies, Moreover, SBRT has acceptable local control rates and low-treatment toxicity.
Relation:	Medicine, v.99, n.32, pp.9
Appears in Collections:	[Dept. of Hospital and Health (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	615	View/Open

Loading...